FGF23 treatment led to changes in renal NaPi-IIa and Vdr protein expression. Larissa Kägi Carla Bettoni Eva M. Pastor-Arroyo Udo Schnitzbauer Nati Hernando Carsten A. Wagner 10.1371/journal.pone.0195427.g006 https://plos.figshare.com/articles/figure/FGF23_treatment_led_to_changes_in_renal_NaPi-IIa_and_Vdr_protein_expression_/6283667 <p>Representative western blots of total renal protein homogenates from mice injected with either vehicle (Ctrl) or recombinant human FGF23 (rhFGF23) once a day for two consecutive days using antibodies against NaPi-IIa <b>(A)</b>, full length Klotho <b>(B)</b>, Cyp24a1 <b>(C)</b> and Vdr <b>(D)</b>. The proteins of interest are shown in the top panels, whereas the corresponding β-actin signal is shown in the bottom image. Densitometric quantification was normalized to the corresponding β-actin values. Bar graphs represent mean ± SD (n = 5-6/group) of the normalized values and data was analyzed by unpaired student’s t-test with significant p values indicated as: * p ≤ 0.05.</p> 2018-05-17 08:17:15 2 D 3 fibroblast growth factor 23 vitamin D metabolizing enzymes 2 D 3 synthesis OH Pi 2 D 3 Background extrarenal tissues Cyp 24a 25- hydroxylases CYP 2R vitamin D hydroxylases 27A 27B expression 2 D 3 treatment 24- hydroxylase CYP 24A catalyzes vitamin D receptor VDR cytochrome P 450 FGF 23 PTH